Journal
- MedComm Introduction
- Molecular Biomedicine Introduction
- Signal Transduction and Targeted Therapy Introduction
- MedComm | Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
- Molecular Biomedicine | The bone marrow niche components are adversely affected in sepsis
Chief-in-Editor：
Carlo M.Croce
Yu-quan Wei
Chief-in-Editor：
Arnold J.M.Driessen
Yu-quan Wei
Chief-in-Editor：
James H.Naisimth
Yu-quan Wei
Journal
- MedComm Introduction
- Molecular Biomedicine Introduction
- Signal Transduction and Targeted Therapy Introduction
- MedComm | Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
- Molecular Biomedicine | The bone marrow niche components are adversely affected in sepsis
Although many studies on the COVID-19 epidemic in China have been published since the outbreak began, very few, if not none, have been useful to real-time epidemic control. None have proposed methods to identify areas at risk or to allocate (or reallocate) scarce health-care resources at a fine enough scale to effectively inform epidemic control on the ground. This situation is common to many infectious diseases, particularly epidemics, which have become increasingly multifactorial and dynamic as a result of rapid urbanisation, population growth and mobility, globalisation of travel and trade, and climate change.
The Lancet. Global health
West China Fourth Hospital
With over 2 million new cases annually, stroke is associated with the highest disability-adjusted life-years lost of any disease in China. The burden is expected to increase further as a result of population ageing, an ongoing high prevalence of risk factors (eg, hypertension), and inadequate management. Despite improved access to overall health services, the availability of specialist stroke care is variable across the country, and especially uneven in rural areas. In-hospital outcomes have improved because of a greater availability of reperfusion therapies and supportive care, but adherence to secondary prevention strategies and long-term care are inadequate. Thrombolysis and stroke units are accepted as standards of care across the world, including in China, but bleeding-risk concerns and organisational challenges hamper widespread adoption of this care in China. Despite little supporting evidence, Chinese herbal products and neuroprotective drugs are widely used, and the increased availability of neuroimaging techniques also results in overdiagnosis and overtreatment of so-called silent stroke. Future efforts should focus on providing more balanced availability of specialised stroke services across the country, enhancing evidence-based practice, and encouraging greater translational research to improve outcome of patients with stroke.
The Lancet. Neurology
West China Hospital, Sichuan University
